Antigen-Free Screening Finds Antibody Biomarkers For Alzheimer's Diagnosis
This article was originally published in Start Up
Executive Summary
Use of a library of synthetic peptide-like molecules as a screen to identify disease-specific antibodies in serum has led to identification of biomarkers for Alzheimer's disease that could form the basis of a blood-based diagnostic test. The screening strategy may also be broadly applicable to the development of diagnostics for other diseases, for identifying antibody targets in autoimmune diseases, and even as the basis for vaccine development.
You may also be interested in...
Alzheimer's Dx: An Essential Piece of the Puzzle
Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.
New Alzheimer's Disease Target and a Potentially Broad Drug Discovery Approach
Researchers have identified a new target in Alzheimer's disease--the natural substrate of an enzyme that itself has long been a target for AD drug development. That the molecule appears to be druggable is itself a surprising observation that may offer valuable insight into how to improve AD drugs. More than that, however, it suggests that substrates of protease inhibitors may provide a completely new set of drug targets in a variety of diseases.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.